The Supervisory Board of Biofrontera AG appointed Paul Böckmann to the company's Executive Board, initially for a limited time until August 31, 2022. Mr. Böckmann will support the current sole member of the Executive Board, Ludwig Lutter, as interims manager. Paul Böckmann is an independent management consultant and coach specializing in particular in global commercialization strategies, international business expansion and complex international reorganizations.
He has worked for various pharmaceutical companies, including CSL Behring AG and Sanochemia, and has specialized in the international commercialization of plasma derivatives since 2016. Since 2021, he has been advising internationally operating plasma companies on product commercialization and reorganization of their business activities with his own consulting company. In particular, he is to be involved in the above-mentioned dialogues between Biofrontera AG and Biofrontera Inc. to develop appropriate solutions for this process.